Showing results (51-60 of 114) with videos related to

Sort By:
Pageof 12
The Journal of International Medical Research|January 1, 1985
A double-blind controlled subjective study of a new pharmaceutical preparation of lormetazepam versus placebo in patients with chronic sleep disturbancesG Meco, L Lestingi, M R Barbieri, et al.
Acta Neurologica Scandinavica|March 3, 1998
Mortality in a population-based cohort of patients treated with antiparkinsonian drugsR Raschetti, S Spila-Alegiani, N Vanacore, et al.
Italian Journal of Neurological Sciences|June 1, 1988
Complicated migraine: case reportG Meco, L Bozzao, R Formisano, et al.
Italian Journal of Neurological Sciences|February 1, 1989
The role of the thymus in multiple sclerosisV D'Andrea, G Meco, F Corvese, et al.
Acta Psychiatrica Belgica|January 1, 1983
Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspectsG Meco, M Casacchia, M Attenni, et al.
Neuropsychobiology|January 1, 1977
Changes in pituitary hormones serum levels in bromocryptine-treated parkinsonian patientsA Polleri, A Carolei, E Rolandi, et al.
Pharmacological Research Communications|March 1, 1983
Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's diseaseM Casacchia, G Meco, F Castellana, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 5, 2003
Excessive daytime somnolence in Parkinson's disease. Follow-up after 1 year of treatmentG Fabbrini, P Barbanti, C Aurilia, et al.
Italian Journal of Neurological Sciences|February 1, 1986
Multicenter trial of L-Deprenyl in Parkinson diseaseS Ruggieri, A Denaro, G Meco, et al.
Minerva Medica|November 3, 1976
[Neuroendocrine aspects of Parkinson's disease. Therapeutic/effect of a prolactin inhibitor]A Agnoli, M Casacchia, A Carolei, et al.
Pageof 12